Maria João d’Aguiar

  • Citations Per Year
Learn More
A prognostic interpretation of preneoplastic lesions would have impact in bronchial carcinoma early diagnosis and through the study of Erb-B family receptors as they have an important role in lung carcinogenesis. The existence of drugs as tyrosine kinase inhibitors stressed the importance of studying gene alterations for selected chemoprevention schemes and(More)
Although lung cancer continues to be the leading cause of cancer-related death, accurate diagnosis followed by personalized treatment is expected to raise the 5-year survival rate. Targeted therapies are now in routine clinical use, in particular for lung adenocarcinoma (ADC). Fibroblast growth factor receptor 1 (FGFR1) has recently emerged as a molecular(More)
INTRODUCTION Multiple studies have reported strong associations between Helicobacter pylori (Hp) inflammation and gastric cancer (GC) development. Altered expressions of pro/anti-inflammatory cytokines have a crucial role in Hp and GC proliferation. Although there are many studies related to cytokines polymorphisms involvement in GC risk, the role of(More)
MicroRNAs (miRNAs) are a class of naturally occurring small non-coding RNAs that target protein-coding mRNAs at the post-transcriptional level. Expression profiling has identified miRNA signatures in cancers that associate with diagnosis, staging, progression, prognosis, and response to treatment. MiRNAs are ideal biomarkers in FFPE-tissue because, unlike(More)
Lung cancer is the most common cause of cancer deaths in both men and women. Adenocarcinoma represents about 28% of the NSCLC cases in men and 42% in women. EGFR is a member of the ERBB family of tyrosine kinases (TK). EGFR mutations are more frequently observed in female, non-smokers, East-Asian and in patients with adenocarcinomas, and predict response to(More)
Lung adenocarcinoma represents about 42% and 28% of NSCLC in women and men. Adenocarcinomas incidence is still rising being the most frequent type of NSCLC diagnosed in USA. Both EGFR and KRAS gene mutations can contribute to the development of NSCLC, namely adenocarcinomas. EGFR and KRAS mutations are considered by some authors as mutually exclusive(More)
  • 1